Potential pharmacological Therapeutics options for COVID-19: Review

Abstract

Unusual pneumonia result from unknown pathogen was emerged in December 2019 in a seafood market of Wuhan city in China. The pathogen was soon identified as a novel coronavirus (2019-nCoV), which is closely related to sever acute respiratory syndrome CoV (SARS-CoV) which has taken the world to the edge of health emergency. On 11th March 2020, COVID-19 was declared a pandemic by the World Health Organization. SARS-CoV-2 belongs to the family of Coronaviridae. Corona virus has been reported to cause similar morbific impacts on the lower respiratory system. Transmits occurs when people breathe in air contaminated by droplets and small airborne particles. Transmission can also occur if sprayed with contaminated fluids, in the eyes, nose or mouth. People remain contagious for up to 20 days, and can spread the virus even if they do not develop any symptoms. Although this disease primarily targets lungs, damages in other organs, such as heart, kidney, liver, and testis, may occur.